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Background: Cannabinoid receptor CB2 (CB2R) and GPR55 are overexpressed in cancer cells and control cell fate.
Results: In cancer cells, CB2R and GPR55 form heteromers that impact the signaling of each protomer.
Conclusion: CB2R-GPR55 heteromers drive biphasic signaling responses as opposed to the individual receptors via
cross-antagonism.
Significance: These heteromers may explain some of the biphasic effects of cannabinoids and, therefore, constitute potential
new targets in oncology.
The G protein-coupled receptors CB2 (CB2R) and GPR55 are
overexpressed in cancer cells and human tumors. Because a
modulation of GPR55 activity by cannabinoids has been sug-
gested, we analyzedwhether this receptor participates in canna-
binoid effects on cancer cells. Here we show that CB2R and
GPR55 form heteromers in cancer cells, that these structures
possess unique signaling properties, and that modulation of
these heteromers can modify the antitumoral activity of canna-
binoids in vivo. These findings unveil the existence of previously
unknown signaling platforms that help explain the complex
behavior of cannabinoids and may constitute new targets for
therapeutic intervention in oncology.
G protein-coupled receptors participate in the control of
many different physiological processes, and their deregulation
contributes to numerous human diseases (1, 2). Two decades
ago, cannabinoid receptor type 1 (CB1R)6 and type 2 (CB2R)
were identified and cloned (3). They are part of the endocan-
nabinoid system, which consists at least of these two receptors,
their endogenous ligands (the endocannabinoids), and the
enzymes that produce andmetabolize these signaling lipids (3).
This system modulates a wide variety of physiological func-
tions, including cell fate (3, 4). Therefore, it has been described
that cannabinoids, in most cases via CB1R and/or CB2R, direct
cells toward proliferation, differentiation, or death, depending
on the cell type and its specific context (5). In tumor cells in
particular, these compounds usually produce proliferation-in-
hibiting and death-inducing effects both in vitro and in vivo (6),
making them promising therapeutic options for the manage-
ment of cancer. More recently, another G protein-coupled
receptor, G protein-coupled receptor 55 (GPR55), has been
related to cannabinoids (7). In this case, the pharmacology of
the receptor is controversial, and, although some authors have
reported cannabinoid actions via GPR55, to date, this receptor
does not formally belong to the cannabinoid receptor family (8).
Several publications support that lysophosphatidylinositol
(LPI), another signaling lipid, is a putative GPR55 endogenous
ligand (9, 10). Like its close relatives CB1R and CB2R, GPR55
has been implicated in the control of cancer cell fate (11). Spe-
cifically, this receptor promotes cancer cell proliferation both
in cell cultures and in animal models of cancer (12–14). How-
ever, the mechanistic details behind these effects remain
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unclear, in part because of the lack of clarity regarding the phar-
macology of the receptor.
The classical pharmacological paradigm associating one
ligand with one receptor and one receptor with one signaling
pathway is being replaced with the view that G protein-coupled
receptor-receptor interactions are an important mechanism
that can modulate the pharmacological properties of each
protomer (15). Here we aimed to determine whether CB2R and
GPR55, two receptors that are overexpressed in most human
tumors and control cancer cell fate (6, 12, 13), can form hetero-
mers in cancer cells and, if so, whether these complexes might
play a role in cannabinoid signaling in tumors.
EXPERIMENTAL PROCEDURES
Cells, Cell Cultures, and Transfections—HEK293 AD cells
stably expressing CB2R (HEK-CB2) or HA-GPR55 (HEK-
GPR55) or coexpressing both receptors (HEK-CB2-GPR55)
were developed as described previously (16, 17). All HEK293-
derived cells were grown in DMEM (Invitrogen) supplemented
with 2 mM L-glutamine, 100 g/ml sodium pyruvate, 100
units/ml penicillin/streptomycin, minimal essential medium
non-essential amino acid solution (1/100), and 10% (v/v) heat-
inactivated FBS (Invitrogen) in the presence of the correspond-
ing selection antibiotic (0.2 mg/ml of zeocin for HEK-CB2
cells, 0.3 mg/ml of G418 for HEK-GPR55 cells, or 0.2 mg/ml of
zeocin and 0.3 mg/ml of G418 for HEK-CB2-GPR55 cells).
BT474 human breast adenocarcinoma cells endogenously ex-
pressing CB2R and GPR557 or stably transfected with a 3HA-
GPR55 construct (BT474-GPR55) and selected by FACS were
maintained in RPMI medium supplemented with 10% FBS,
penicillin/streptomycin, and 0.4mg/ml G418. Human glioblas-
tomaT98G cells endogenously expressing CB2R andGPR55 (at
similar levels as BT474 cells)7 or stably transfected with selec-
tive CB2R or GPR55 shRNAs (Genecopoeia, Rockville, MD)
and selected by FACS were grown in DMEM supplemented
with 2 mM L-glutamine, 100 g/ml sodium pyruvate, 100
units/ml penicillin/streptomycin, minimal essential medium
non-essential amino acid solution (1/100), and 10% (v/v) heat-
inactivated FBS in the presence of the corresponding selection
antibiotic (5 g/ml puromycin for T98G-shGPR55 and T98G-
shCB2). For transient transfections, HEK293 and BT474 cells
were transfected with the corresponding fusion protein cDNA
by the PEI (Sigma) method (18).
Bioluminescence Resonance Energy Transfer (BRET)—For
BRET, GPR55-Rluc, CB2R-YFP, and Ghrelin 1a receptor-YFP
fusion proteins were obtained as follows. The human cDNAs
for CB2R, GPR55, or the Ghrelin 1a receptor were cloned into
pcDNA3.1 and amplified without their stop codons using sense
and antisense primers harboring unique EcoRI andBamHI sites
for CB2R or the ghrelin receptor or harboring HindIII and
BamHI for GPR55. The amplified fragments were subcloned to
be in-frame with Renilla luciferase (Rluc) into the EcoRI and
BamHI restriction sites of the pcDNA3.1-RLuc vector (pRLuc-
N1, PerkinElmer Life Sciences) or the pEYFP-N1 vector
(enhanced yellow variant of GFP, Clontech, Heidelberg, Ger-
many) to generate the plasmids that express proteins fused to
RLuc or YFP on the C-terminal end (GPR55-RLuc, CB2R-YFP,
andGhrelin 1a receptor-YFP). The expression of the constructs
was tested as described previously (19). HEK293 or BT474 cells
were transiently cotransfected with a constant amount of
cDNA encoding for proteins fused to Rluc as a BRETdonor and
with increasing amounts of the cDNA corresponding to pro-
teins fused to YFP as a BRET acceptor. The fusion protein
expression and BRET values were quantified as described pre-
viously (20) using a Mithras LB 940 that allows the integration
of the signals detected in the short wavelength filter at 485 nm
(440–500 nm) and the long wavelength filter at 530 nm (510–
590 nm) (20). The net BRET is defined as [(long wavelength
emission)/(short wavelength emission)]  Cf, where Cf corre-
sponds to [(longwavelength emission)/(shortwavelength emis-
sion)] for the donor construct expressed alone in the same
experiment. Data were fitted to a non-linear regression equa-
tion, assuming a single phase saturation curve with GraphPad
Prism software (GraphPad, San Diego, CA). BRET is expressed
asmilliBRETunits (net BRET 1000). In saturation curves, the
relative amount of BRET is given as a function of 100 the ratio
between the fluorescence of the acceptor (YFP) and the lucifer-
ase activity of the donor (Rluc).
In Situ Proximity Ligation Assays (PLA)—Cells were grown
on glass coverslips and fixed in 4% paraformaldehyde, washed
with PBS containing 20 mM glycine, permeabilized with the
same buffer containing 0.05% Triton X-100, and washed suc-
cessively with PBS. CB2R-GPR55 heteromers were detected
using the Duolink II in situ PLA detection kit (Olink, Biosci-
ence, Uppsala, Sweden). After 1 h of incubation at 37°Cwith the
blocking solution in a preheated humidity chamber, cells were
incubated overnight in the antibody dilution medium with a
mixture of equal amounts of mouse anti-HA antibody (1:100,
Sigma) or rabbit anti-GPR55 antibody (1:100, Abcam, Cam-
bridge, UK) coupled directly to a DNA minus chain to detect
HA-GPR55 or endogenous GPR55 and rabbit anti-CB2R anti-
body (1:100, Cayman Chemical, Ann Arbor, MI) coupled
directly to a DNA plus chain. Cells were washed with wash
buffer A at room temperature and incubated in a preheated
humidity chamber for 30 min at 37°Cwith the ligation solution
(Duolink II ligation stock, 1:5, and Duolink II ligase, 1:40) to
induce annealing and ligation of the two DNA probes. Ampli-
ficationwas donewith theDuolink II detection reagents red kit,
which contains fluorescence nucleotides. After exhaustive
washing at room temperature with wash buffer B, cells were
mounted using mounting medium with DAPI. The samples
were observed under a Leica SP2 confocal microscope (Leica
Microsystems, Mannheim, Germany). Red fluorescent images
were processed with ImageJ software. PLA requires that both
receptors be close enough to allow the two different antibody-
DNA probes to be able to ligate (17 nm) (21, 22). If the recep-
tors are within sufficient proximity, a punctate fluorescent sig-
nal can be detected by confocal microscopy.
Dynamic Mass Redistribution (DMR) Assays—The agonist-
induced cell global signaling signaturewas determined by label-
free technology measuring the DMR using an EnSpiremulti-
7 E. Moreno, C. Andradas, M. Medrano, M. M. Caffarel, E. Pérez-Gómez, S.
Blasco-Benito,M.Gómez-Cañas,M. R. Pazos, A. J. Irving, C. Lluís, E. I. Canela,
J. Fernández-Ruiz, M. Guzmán, P. J. McCormick, and C. Sánchez, unpub-
lished data.
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mode plate reader (PerkinElmer Life Sciences) (23). Refractive
waveguide grating optical biosensors, integrated in 384-well
microplates, allowed measurements of changes in local optical
density in a detection zone up to 150 nm above the surface of
the sensor. Cellular mass movements induced upon receptor
activation were detected by illuminating the underside of the
biosensor with polychromatic light andmeasured as changes in
wavelength of the reflectedmonochromatic light that is a func-
tion of the index of refraction. The magnitude of this wave-
length shift (in picometers) is directly proportional to the
amount of cell movement. Briefly, 24 h before the assay, cells
(10,000 cells/well) were seeded in 384-well sensor microplates
and cultured to obtain 70–80% confluent monolayers. Before
the assay, cells were washed twice with assay buffer (Hanks’
balanced salt solution with 20 mM HEPES (pH 7.15)) and incu-
bated for 2 h in assay buffer with 0.1% dimethyl sulfoxide in the
reader at 24 °C. Thereafter, the sensor plate was scanned, and a
baseline optical signature was recorded before adding the test
compounds dissolved in assay buffer containing 0.1% dimethyl
sulfoxide. DMR responses were monitored for at least 2000 s.
Kinetic results were analyzed using EnSpire workstation soft-
ware version 4.10.
cAMP Production—Homogeneous time-resolved (TR) fluo-
rescence energy transfer (FRET) assays were performed using
the Lance Ultra cAMP kit (PerkinElmer Life Sciences) on the
basis of the competitive displacement of a europium chelate-
labeled cAMP tracer bound to a specific antibody conjugated to
acceptor beads.We first established the optimal cell density for
an appropriate fluorescent signal. This was done by measuring
the TR-FRET signal, determined as a function of forskolin con-
centration using different cell densities. The forskolin dose-
response curves were related to the cAMP standard curve to
establish which cell density provides a response that covers
most of the dynamic range of the cAMP standard curve. Cells
(1000 cells/well) were pretreated with the antagonists or the
corresponding vehicle (dimethyl sulfoxide) in white ProxiPlate
384-well microplates (PerkinElmer Life Sciences) at 25 °C for
20 min and stimulated with agonists for 15 min before adding
0.5 M forskolin or vehicle and incubating for an additional
15-min period. Fluorescence at 665 nm was analyzed on a
PHERAstar Flagship microplate reader equipped with a homo-
geneous time-resolved fluorescence energy transfer optical
module (BMG Lab Technologies, Offenburg, Germany).
ERK-1/2 Phosphorylation—Cells (35,000 cells/well) seeded
in 96-well poly-D-lysine-coated plates (Sigma-Aldrich) were
pretreated at 25 °C for 20 min with the antagonists and stimu-
lated for an additional 7 min with the indicated agonists. Phos-
phorylation was determined in white ProxiPlate 384-well
microplates (PerkinElmer Life Sciences) by -screen bead-
based technology using the amplified luminescent proximity
homogeneous assay kit (PerkinElmer Life Sciences) and the
Enspire multimode plate reader (PerkinElmer Life Sciences).
Phosphorylation is expressed in arbitrary units, ALPHAcounts,
as measured by light emission at 520–620 nm by the acceptor
beads. To evaluate phospho-ERK-1/2 expression in tumors, a
Western blot analysis was performed. Tumor lysates were sub-
jected to SDS-PAGE, and proteins were transferred onto poly-
vinylidene fluoridemembranes. Blotswere incubatedwith anti-
phospho-ERK (Thr-202/Tyr-204), anti-ERK (Cell Signaling
Technology, Danvers, MA), and anti--tubulin (Sigma-Al-
drich) antibodies. Luminograms were obtained with the Amer-
sham Biosciences enhanced chemiluminescence detection kit
(GEHealthcare), and the densitometric analysis was performed
with Quantity One software (Bio-Rad).
[35S]GTPS Binding Assays—HEK-GPR55 cells were rinsed
twice in phosphate-buffered saline, detached from dishes by
incubation with a buffer containing 5.6 mM glucose, 5 mM KCl,
5 mM HEPES, 137 mM NaCl, and 1 mM EGTA (pH 7.4), and
collected by centrifugation (500  g) at 4 °C. The pellets were
then resuspended in ice-cold lysis buffer (0.2 mM MgSO4, 0.38
mMKH2PO4, 0.61mMNa2HPO4, and 0.5% PMSF (pH 7.4)) and
homogenized by vortexing. HEK-GPR55 membranes were iso-
lated by centrifugation (20,000 g for 20min), and pellets were
resuspended in 50 mM Tris-HCl buffer (pH 7.4). Protein con-
centration was determined by detergent compatible protein
assay kit (Bio-Rad). Membranes were stored at 80 °C until
used for analysis of LPI-induced stimulation of [35S]GTPS
binding. For this analysis, we followed a procedure published
previously (24) in which cell membranes (20 g of protein/ml)
were incubated for 120 min at 30 °C in assay buffer (100 mM
NaCl, 50mMTris-HCl, 10mMMgCl2, 1mM EGTA, 1mMDTT,
50 M GDP, and 1 mg/ml BSA (pH 7.4)) containing 0.1 nM
[35S]GTPS and increasing concentrations of LPI (1010-105
M) in the presence or absence of 106 M 9-tetrahydrocannab-
inol (THC, The Health Concept, Richelbach, Germany). Non-
specific binding was determined in the presence of 10M unla-
beled GTPS. Reactions were terminated by rapid filtration
performed by aHarvester Filtermate (PerkinElmer) with Filter-
mate A GF/C filters. Filters were rinsed nine times with wash-
ing buffer (50mMTris-HCl and 1mg/ml BSA (pH 7.4)) and left
to dry, andmelt-on scintillation pads (Meltilex A, Perkin Elmer
Life Sciences) were melted onto them. The bound radioactivity
was quantified by a liquid scintillation spectrophotometer
(Wallac MicroBeta Trilux, PerkinElmer Life Sciences). Results
were normalized as percent change over basal level (set at
100%) and corresponded to three separate experiments, each
performed in triplicate. Data were analyzed by nonlinear
regression analysis of sigmoidal dose-response curves using
GraphPad Prism 5.01.
Tumor Generation and Animal Treatments—Tumors were
induced in 6-week-old athymicmale mice (n 6/experimental
group; Harlan Interfauna Iberica, Barcelona, Spain) by subcu-
taneous injection of 10 106T98Ghumanglioblastoma cells in
PBS supplemented with 0.1% glucose. Half of the animals were
treated with double-stranded RNA duplexes for humanGPR55
(ON-TARGETplus SMARTpools) from Dharmacon-Thermo
Scientific (Lafayette, CO). The sequences were 5-GAAUUCC-
GCAUGAACAUCAUU-3, 5-GAGAAACAGCUUUAUCG-
UAUU-3, 5-AAGAACAGGUGGCCCGAUUUU-3, and 5-
GCUACUACUUUGUCAUCAAUU-3. The other half was
treated with a non-targeted control siRNA from Applied
Biosystems-Ambion (Austin, TX). The sequence was 5-UUC-
UCCGAACGUGUCACGUtt-3. siRNAwasmixedwithAtelo-
Gene (Koken, Tokyo, Japan) and injected locally when tumors
reached approximately 200 mm3 (day 1) and on day 7. At the
same time, each groupwas treated peritumorallywithTHC (1.5
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FIGURE 1. Expression and functional characterization of CB2R-GPR55 heteromers in transfected HEK293 cells. A, BRET saturation experiments were
performed in cells transfected with a fixed amount of GPR55-Rluc cDNA (0.5 g) and increasing amounts (1–5 g) of CB2R-YFP or Ghrelin 1a receptor-YFP
cDNAs. Values are the mean S.E. of three to six different experiments grouped as a function of the amount of BRET acceptor.mBU, milliBRET unit. B–J, DMR
in HEK-CB2 (B and C), HEK-GPR55 (D and E), or HEK-CB2-GPR55 (F–I) cells not treated (B, D, F, and G) or treated overnight with 10 ng/ml PTX or with 100 ng/ml
CTX prior to the addition of the antagonists HBA (B and G) or AM630 (D and F) and stimulation with LPI or HU-308. The resulting picometer (pm) shifts of
reflected light wavelength versus time were monitored. Each curve is the mean of a representative optical trace experiment carried out in triplicates.
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or 15 mg/kg/day) (The Health Concept) or the corresponding
vehicle (PBS supplemented with 5% BSA) for 15 days. Tumors
weremeasured routinely with external calipers, and the volume
was calculated as (4/3) (width/2)2 (length/2). At the end
of the treatment, animals were sacrificed, and tumors were
collected.
RESULTS
Expression and Functional Characterization of CB2R-GPR55
Heteromers in Transfected HEK293 Cells—To analyze the pos-
sible molecular interaction between CB2R and GPR55, BRET
experiments were performed. HEK293 cells expressing a fixed
amount of GPR55-Rluc as the BRET donor and increasing
amounts of CB2R-YFP as the BRETacceptor generated a hyper-
bolic and saturable BRET signal (Fig. 1A) with a BRETmax of
257  18 milliBRET units and a BRET50 of 7.3  1.2 that was
not evident in cells expressing equivalent amounts of GPR55-
Rluc and Ghrelin 1a receptor-YFP as a negative control (Fig.
1A). These results support that CB2R and GPR55 form hetero-
mers in cotransfected cells.
We then analyzed whether the formation of these complexes
alters the signaling properties of the individual protomers. To
test which G proteins are coupled to the receptors when
expressed alone, we used a label-free approach that measures
DMR in the bottom 150 nm of a cell monolayer through detec-
tion of changes in light diffraction (23). In HEK293 cells
expressing CB2R only (HEK-CB2), the CB2R-selective agonist
FIGURE 2. cAMPsignaling inHEK293 cells expressing single receptors or CB2R-GPR55heteromers. cAMPproduction inHEK-CB2 (A–C), HEK-GPR55 (D and
E), or HEK-CB2-GPR55 cells (F and G) treated (A and F) or not treated (B–E and G) overnight with 10 ng/ml PTX or with 100 ng/ml CTX. Cells were preincubated
with vehicle or with the antagonists AM630 or HBA and stimulated with increasing concentrations of HU-308 or LPI in the absence or presence of 0.5 M FK.
Values are mean S.E. of n 4–7 and are expressed as a percentage of the FK-treated cells in each condition. One-way ANOVA followed by Bonferroni post
hoc test showed a significant effect over vehicle-treated cells (*, p 0.05; **, p 0.01; ***, p 0.001) or over the FK effect (##, p 0.01; ###, p 0.001).
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HU-308 produced a robust DMR signal (Fig. 1B) that was sen-
sitive to pertussis toxin (PTX) but not to cholera toxin (CTX)
(Fig. 1C). This is in line with many previous reports showing
coupling of CB2R to Gi heterotrimeric proteins (3). In HEK293
cells expressing GPR55 only (HEK-GPR55), we observed that
the GPR55 agonist LPI produced a strong response (Fig. 1D)
that was insensitive to CTX or PTX treatment (Fig. 1E), sugges-
tive of coupling to G proteins other than Gi and Gs, as reported
previously (8). Importantly, neither LPI nor HU-308 showed
any activity in non-transfected cells (Fig. 1J), and both CB2R
and GPR55 agonists and antagonists showed selectivity for
their respective receptors with no agonist activation or antago-
nist blockade of the partner receptor in single receptor-ex-
pressing cells (Fig. 1, B and D). Interestingly, in HEK293 cells
overexpressing both receptors (HEK-CB2-GPR55), we ob-
served a similar coupling to G proteins but a different pharma-
cological behavior. In these cells, LPI induced a robust DMR
signal (Fig. 1F) that was insensitive to CTX or PTX treatment
(Fig. 1,H and I), again suggesting coupling to G proteins differ-
ent fromGi and Gs, and HU-308 induced a signal (Fig. 1G) that
was blocked by PTX but not by CTX (Fig. 1,H and I), indicating
a Gi coupling. Surprisingly, the signal induced by LPI was com-
pletely blocked by the CB2R antagonist AM630 (Fig. 1F), and
the signaling induced by HU-308 was blocked by the GPR55
antagonist 4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-
1H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-5-yl] benzoic acid (HBA)
(Fig. 1G). This cross-antagonism phenomenon suggests that,
through the heteromer, one receptor can be targeted by using
the partner receptor antagonist.
Because DMR experiments are indicative of global receptor
signaling, we next investigated heteromer function in specific
signaling pathways. In HEK-CB2 cells, HU-308 (Fig. 2A), but
not LPI (Fig. 2B), prevented the increase in cAMP levels elicited
by forskolin (FK), an effect that was blocked by PTX but not by
CTX (Fig. 2A) and by AM630 but not by HBA (Fig. 2C). In
HEK-GPR55 cells, LPI produced no effect on FK-induced
FIGURE 3. ERK-1/2 phosphorylation in HEK293 cells expressing single receptors or CB2R-GPR55 heteromers. A and B, ERK-1/2 phosphorylation was
determined in HEK-CB2 (black columns) or HEK-GPR55 (white columns) cells stimulated with 0.1 M HU-308 or 1 M LPI for different times (A) or for 7 min with
increasing concentrations of HU-308 or LPI (B). C–E, ERK-1/2 phosphorylation was determined in HEK-CB2-GPR55 cells stimulated with 0.1 M HU-308 or 1 M
LPI for different times (C), with increasing concentrations of these compounds for 7min (D), or in cells pretreated with vehicle (white columns), with HBA (gray
columns), or AM630 (black columns) prior to stimulation with HU-308, LPI, or both (E). Phosphorylation was expressed in arbitrary units (ALPHA counts, light
emission at 520–620 nm). Values are mean  S.E. of n  6–9 and are expressed as a percentage over vehicle-treated cells. One-way ANOVA followed by
Bonferroni post hoc test showed a significant effect over vehicle-treated cells (*, p 0.05; **, p 0.01; ***, p 0.001) or of the antagonist plus agonist over the
agonist treatment (E; ##, p 0.01; ###, p 0.001).
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cAMP levels (Fig. 2D), supporting coupling of this receptor toG
proteins different from Gi or Gs. HU-308 did not induce any
effect in these cells either (Fig. 2E). As observed in the label-free
assays, HEK-CB2-GPR55 cells showed a different pharmaco-
logical behavior. HU-308 alone was still able to block the FK-
induced cAMP increase through a PTX-sensitive mechanism
(Fig. 1F). As expected in these cells, LPI was not able to increase
or decrease (Fig. 1G) FK-stimulated cAMP levels. However,
simultaneous activation of CB2R and GPR55 prevented HU-
308 action (Fig. 1G), which is indicative of a negative cross-talk
between both receptors. Moreover, in HEK-CB2-GPR55 cells,
HU-308 effects on cAMP levels were blocked not only by
AM630 but also by HBA (Fig. 1G). Similar negative cross-talk
and cross-antagonism were detected in ERK-1/2 signaling.
When expressed alone, activation of each receptor by its selec-
tive ligand resulted in a time- and dose-dependent increase in
ERK-1/2 phosphorylation (Fig. 3, A and B). In cells expressing
both receptors simultaneously, the activation of any of the
protomers individually produced a similar response (Fig. 3, C
and D). However, coactivation of both receptors resulted in
reduced ERK-1/2 phosphorylation (Fig. 3E). In addition, LPI-
induced ERK-1/2 phosphorylation was prevented by the CB2R
antagonist, and HU-308 action was blocked by the GPR55
antagonist (i.e. cross-antagonist) (Fig. 3E). Together, these
results support that CB2R and GPR55 form heteromers in
cotransfected cells and that, via these complexes, agonists and
antagonists of one receptor are able to impair the signaling of
the partner receptor.
Expression and Functional Characterization of CB2R-GPR55
Heteromers in Human Breast Cancer Cells—Next we sought to
determine whether CB2R-GPR55 heteromers are present in a
more physiological setting, i.e. human cancer cells. First, BRET
saturation curves performed in human breast adenocarcinoma
BT474 cells transfected to express GPR55-Rluc and increasing
amounts of CB2R-YFP indicated that these receptors also inter-
act in cancer cells (Fig. 4A). This interaction was confirmed
further by PLAs in BT474 cells endogenously expressing CB2R
and stably expressing HA-GPR55 (BT474-GPR55). Hetero-
merswere readily detectable in these cells (Fig. 4B,upper panel)
but not in cells not expressing CB2R or upon removal of one of
the primary antibodies (Fig. 4B, bottom panels). Of interest, the
PLA-positive BT474 cells showed the same signaling profile as
the aforementionedHEK-CB2-GPR55 cells. In label-free exper-
iments, HU-308 induced a DMR signal that was sensitive to
PTX and not to CTX, LPI induced a signal that was insensitive
to toxins, and both LPI- and HU308-induced signals were
FIGURE 4. Expression and functional characterization of CB2R-GPR55 heteromers in BT474 human breast cancer cells. A, BRET saturation experiments
were performed in BT474 cells transfectedwith 1g of GPR55-Rluc cDNA and increasing amounts of CB2R-YFP cDNA (1–3g). Values are given as themean
S.E. of three to sevendifferent experiments groupedas a functionof the amount of BRET acceptor.mBU,milliBRETunits.B, representative result of an in situPLA
performed in BT474-HA-GPR55 cells (upper panel). In the confocal microscopy image (superimposed sections) heteromers appear as red spots. Cell nuclei were
stainedwith DAPI (blue). As negative controls (bottom panels), PLAwere performed in HEK-GPR55 cells in the presence of anti-HA and anti-CB2R antibodies or
in BT474-GPR55 cells in the absence of the anti-HA (CB2R) or the anti-CB2R antibodies (GPR55). Scale bars 20m. C–E, DMR analysis in BT474-HA-GPR55 cells
not treated (C) or treated overnightwith PTX (D, 10 ng/ml) or CTX (E, 100 ng/ml) prior to preincubationwith the CB2R or theGPR55 antagonists (AM630 or HBA,
respectively) and challengedwith LPI orHU-308. The resultingpicometer shifts of reflected lightwavelength (picometer,pm) versus timeweremonitored. Each
curve is the mean of a representative optical trace experiment carried out in triplicates.
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blocked by the antagonist of the partner receptor (Fig. 4, C–E).
In addition, HU-308 (but not LPI) blocked the FK-induced
cAMP increase (Fig. 5A), an effect that was sensitive to PTXbut
not to CTX (Fig. 5B). The HU308-induced effect was also pre-
vented by coactivation with LPI (negative cross-talk) and not
only by a CB2R antagonist but also by a GPR55 antagonist
(cross-antagonism) (Fig. 5A). The negative cross-talk and
cross-antagonism were also observed in the activation of ERK-
1/2 (Fig. 5, C–E). Collectively, these findings support the exis-
tence of CB2R-GPR55 heteromers in cancer cells and show that
these macromolecular structures have specific signaling
properties.
Differential Effects of THC inHEK293 Cells Expressing CB2R-
GPR55 Heteromers or the Single Receptors—Next, we analyzed
the signaling response of HEK293 and cancer cells to the can-
nabinoid agonist THC. In agreement with previous observa-
tions (3), THC dose-dependently reduced FK-increased cAMP
levels (Fig. 6A) and enhanced ERK-1/2 phosphorylation (Fig.
6B) inHEK-CB2 cells. Interestingly, inHEK-CB2-GPR55 cells, a
biphasic responsewas observed in both readouts. Although low
concentrations of THC decreased FK-induced cAMP, higher
THC concentrations attenuated this effect (Fig. 6C). Analo-
gously, low concentrations of THC increased ERK-1/2 phos-
phorylation, whereas higher concentrations reduced this
response (Fig. 6D). In support of the notion that these two-
phase effects of THC are distinctive of the heteromers, we
observed that the U-shaped curve in the cAMP assays (Fig. 6E)
and the bell-shaped curve in the ERK-1/2 activation data (Fig.
6F) became flattened when cells were pretreated with either a
CB2R or a GPR55 antagonist. From these observations, we
FIGURE 5. cAMP production and ERK-1/2 phosphorylation mediated by CB2R-GPR55 heteromers in BT474 cancer cells. A and B, cAMP production in
BT474-GPR55 cells was determined in cells not pretreated (A) or pretreated overnight (B) with 10 ng/ml PTX orwith 100 ng/ml CTX prior to incubationwith the
CB2R antagonists AM630 or SR144528 (SR2) or with the GPR55 antagonist HBA (A) and stimulated with HU-308, LPI, or both in the absence or in the presence
of 0.5 M FK. Values are mean S.E. of n 3–9 and are expressed as a percentage of the FK-treated cells. C–E, ERK-1/2 phosphorylation was determined in
BT474-GPR55 cells stimulated (7min) with increasing concentrations of HU-308 or LPI (C), with 0.1M HU-308 or 1M LPI for different times (D), or pretreated
or not treated with the CB2R antagonists AM630 or SR144528 or with the GPR55 antagonist HBA prior to stimulation with HU-308, LPI, or both (E). Phosphor-
ylation was expressed in arbitrary units (ALPHA counts, light emission at 520–620 nm). Values are mean S.E. of n 3–9 and are expressed as a percentage
of basal levels found in vehicle-treated cells. One-way ANOVA followed by Bonferroni post hoc test showed a significant effect over vehicle-treated cells (***,
p 0.001; **, p 0.01), over FK-treated cells (A and B; ##, p 0.01; ###, p 0.001), or antagonist plus agonist over the agonist treatment (E; ###, p 0.001).
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hypothesize the following mechanistic explanation for the
biphasic action of THC (Fig. 6G). At low concentrations, THC
(a well reported CB2R agonist) signals through CB2R, produc-
ing a conceivable activation of ERK-1/2 and inhibition of FK-
induced cAMP increase (Fig. 6G). At higher concentrations,
THC is able to target GPR55, acting as a receptor antagonist, as
suggested previously in Ref. 25, and exerting a cross-antago-
nism over CB2R through the heteromer, which would result in
an attenuation of the CB2R-mediated effects on ERK-1/2 acti-
vation and cAMP production (Fig. 6G). In support of this idea,
THC (whichwas not able to induce eitherDMR signals or ERK-
1/2 phosphorylation in cells only expressing GPR55) decreased
FIGURE 6.Differential effects of THC in HEK293 cells expressing CB2R-GPR55 heteromers or the single receptors. A–F, cAMP production in the absence
or presence of FK (A, C, and E) and ERK-1/2 phosphorylation (B, D, and F) in response to increasing concentrations of THC in HEK-CB2 (A and B) and HEK-CB2-
GPR55 (C–F) cells. E and F, cells were pretreated with vehicle or the antagonists SR2 or HBA. Phosphorylation was expressed in arbitrary units (ALPHA counts,
light emission at 520–620 nm). Values aremean S.E. of n 5–12 and are expressed as a percentage of FK-treated cells (A, C, and E) or of vehicle-treated cells
(B, D, and F). One-way ANOVA followed by Dunnett’s post hoc test showed a significant effect over the effect of FK (E; #, p 0.05; ##, p 0.01; ###, p 0.001)
or over vehicle-treated cells (F; *, p 0.05; **, p 0.01).G, schematic of the hypothesized effect of THConCB2R-GPR55 heteromers. At low concentrations, THC
acts as a CB2R agonist promoting signaling. At higher concentrations, THC targets GPR55, acting as an antagonist. Via cross-antagonism through the hetero-
mer, highTHCconcentrations inhibit CB2R signaling.H–J, DMR responses (H), ERK-1/2phosphorylation (I), andGTPSbinding (J) inHEK-GPR55cells in response
to LPI and in the absence or presence of THC (J, 1 M). H, the resulting picometer (pm) shifts of reflected light wavelength versus time were monitored. Each
curve is themean of a representative optical trace experiment carried out in triplicate. I, phosphorylationwas expressed in arbitrary units (ALPHA counts, light
emission at 520–620 nm). Values are mean S.E. of n 4–6 and are expressed as a percentage relative to the effect of LPI. One-way ANOVA followed by
Dunnett’s post hoc tests showed a significant (***, p 0.001) effect over the LPI effect. J, [35S]GTPS bindingwas expressed as the percentage over basal, and
values are mean S.E. of n 3, each one run in triplicate.
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LPI-induced DMR responses (Fig. 6H) and ERK-1/2 activation
(Fig. 6I) in HEK-GPR55 cells. The capability of THC to prevent
LPI-induced activation of GPR55 was further confirmed by
GTPS binding assays. LPI produced a marked increase in
[35S]GTPS binding in HEK-GPR55 membranes (Emax 
129 2%; EC50 7.1 3.4 nM), an effect that was completely
blocked by coincubation with THC (Fig. 6J). Together, these
results indicate that, at high concentrations, THC actually
behaves as a GPR55 antagonist.
Involvement of CB2R-GPR55 Heteromers in the Response of
Cancer Cells to THC—We then went back to cancer cells to
challenge this hypothesis. First, PLA experiments showed that
neither low nor high THC concentrations disrupt the CB2R-
GPR55 heteromers (Fig. 7A). Second, as in HEK-CB2-GPR55
cells, a two-phase effect of THCwas observed in BT474-GPR55
cells on themodulation of both cAMP levels andERK-1/2 phos-
phorylation, in which the response found at low concentrations
was attenuated at higher concentrations (Fig. 7B). The U-
shaped curve in the cAMP assays and the bell-shaped curve in
the ERK-1/2 activation became less pronounced or even flat-
tened when BT474-GPR55 cells were pretreated with the
GPR55 antagonist HBA (Fig. 7C), demonstrating that the
antagonistic effect of THC on GPR55 modulates CB2R signal-
ing through CB2R-GPR55 heteromers.
Our hypothesis was further corroborated in T98G cells, a
human glioblastoma cell line that endogenously expresses both
CB2R (26) and GPR55 (12). By PLA, we detected red spots cor-
responding to CB2R-GPR55 heteromers (Fig. 8A, top left
panel). Treatment of cells with either low or high concentra-
tions of THC did not alter this staining (Fig. 8A, top panels),
suggesting that the heteromers are not disrupted by the canna-
binoid. The CB2R-GPR55 complexes were not detected in the
negative controls, in which one of the primary antibodies was
omitted, or in T98G cells, in which CB2R (T98G-shCB2) or
GPR55 (T98G-shGPR55) expression was silenced (Fig. 8A, bot-
tom panels). As in transfected cells, a two-phase effect of THC
was observed in T98G cells on the modulation of both cAMP
levels and ERK-1/2 phosphorylation, in which the response
found at low concentrations was attenuated at higher concen-
trations (Fig. 8B). Finally, we analyzed the strength of our
hypothesis in an in vivo setting. Subcutaneous tumors were
generated by injection of T98G cells into athymic male mice.
Tumors increased their growth slightly in response to a low
THC dose (although no statistical differences were observed),
whereas a higher THC dose produced the opposite effect, i.e. a
significant reduction in tumor growth (Fig. 8C). According to
our hypothesis, the low-dose effect would be produced mainly
via activation of CB2R and the high-dose effect via cross-antag-
onism of CB2R upon targeting of GPR55. The direct antago-
nism of GPR55, a receptor that has been shown previously to
drive tumorigenesis (12–14), by THC may contribute to this
strong antitumoral response. Supporting the idea that GPR55
behaves as a tumor growth brake when targeted by high doses
of THC, we observed that GPR55-silenced tumors increased
their growth when exposed to THC (Fig. 8C). The differential
effects of THC on tumor growth occurred in concert with dif-
ferential changes in the levels of activated ERK-1/2, i.e. a reduc-
tion whenCB2R andGPR55were coexpressed and an enhance-
ment when GPR55 was silenced (Fig. 8,D and E). These results
support our hypothesis and suggest that the well established
cannabinoid target CB2R, as well as GPR55, coparticipate, in
part via direct receptor-receptor interaction, in the control of
tumor growth in response to THC.
DISCUSSION
The findings reported in this study lead to three important
conclusions regarding the role of cannabinoids and their cog-
nate receptors. First, we demonstrate the existence and func-
tion of CB2R-GPR55 heteromers in cancer cells. Second, we
show that the expression of these receptor heteromers has a
major impact on cannabinoid signaling in these cells. Finally,
FIGURE 7. Involvement of CB2R-GPR55 heteromers in the response of
transfected cancer cells to THC. A, representative results of in situ PLAs per-
formed in BT474-HA-GPR55 cells treated (30 min) with high and low THC
concentrations. In the confocal microscopy images (superimposed sections),
heteromers appear as red spots. Cell nuclei were stained with DAPI (blue).
Scale bars 20m. B, the effect of THC on FK-induced cAMP production (left
panel) and ERK-1/2 phosphorylation (right panel) in BT474-HA-GPR55 cells.
Schematics depict the hypothesized THCmechanism of action. C, cAMP pro-
duction (top panel) and ERK-1/2 phosphorylation (bottom panel) in BT474-
GPR55 cells pretreated with vehicle or the GPR55 antagonist HBA prior to
stimulation with THC. Top panel, cells were incubated in the absence or pres-
ence of 0.5 M forskolin. Phosphorylation was expressed in arbitrary units
(ALPHA counts, light emission at 520–620 nm). Values aremean S.E. of n
5–12 and are expressed as a percentage of FK-treated cells (cAMPdetermina-
tion) or of vehicle-treated cells (ERK-1/2 phosphorylation). One-way ANOVA
followedbyDunnett’s post hoc test showeda significant effect over theeffect
of FK (#, p  0.05; ##, p  0.01) or over vehicle-treated cells (F; *, p  0.05;
**, p 0.01; ***, p 0.001).
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our results suggest that direct targeting of CB2R-GPR55 via
appropriate doses of THC may be an effective approach to
reducing tumor growth.
Receptor heteromers involving the sister cannabinoid recep-
tor CB1 have been the focus of intense research. Therefore,
CB1Rs have been shown previously to interact with other G
FIGURE 8. Involvement of CB2R-GPR55 heteromers in the response to THC of cancer cells endogenously expressing CB2R and GPR55. A, top panels,
representative results of in situ PLAs performed in T98G cells treated (30 min) with vehicle and low and high THC concentrations. In the confocal microscopy
images (superimposed sections), heteromers appear as red spots. Cell nuclei were stained with DAPI (blue). Bottom panels, as negative controls, PLAs were
performed in T98G cells in the absence of anti-CB2R antibody (GPR55) or anti-GPR55 antibody (CB2R) or in the presence of anti-GPR55 and anti-CB2R antibodies
in T98G cells in which CB2R (T98G-shCB2) or GPR55 (T89G-shGPR55) was silenced. Scale bars 20 m. B, FK-induced cAMP production (left panel) and ERK-1/2
phosphorylation (right panel) in T98G cells in response to THC. Schematics depict the hypothesized THCmechanism of action. C, the volume of subcutaneous
tumors generated by injection of T98G cells in immunodeficient mice was determined. Tumors were treated with a control siRNA (left panel) or a GPR55-
selective siRNA (right panel), and animals received the indicated doses of THC or the corresponding vehicle (Veh). Tumor growth curves were compared by
ANOVAwith a post hoc analysis by Student-Newman-Keuls test.D and E, Western blot analysis (D) and densitometric analysis (E) of phospho-ERK-1/2 (pERK) in
control siRNA (siC) and GPR55-siRNA tumors treated with 15 mg/Kg THC. *, p 0.05 versus vehicle-treated animals (C) or cells (E).
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protein-coupled receptors, including dopamine D2 receptors
(which promotes a switch in the preferential coupling from Gi
to Gs) (27), D2 receptors and adenosine A2A receptors simulta-
neously (producing a negative modulation of D2 receptor func-
tion by A2A and CB1R agonists) (28), opioid receptors (which
produces a negative cross-talk between protomers) (29), orexin
OX1 receptors (eliciting a positive cross-talk in response to
orexin and cross-antagonism) (30), and angiotensin AT1 recep-
tors (resulting in the potentiation of AT1 receptor signaling)
(31). More recently, coimmunoprecipitation assays in HEK293
cells have suggested that CB1R can form heteromers with
GPR55 (32). In contrast to CB1R, very little is known about the
possible existence and functional relevance of heteromers
involving CB2R. A recent study has shown that CB2R hetero-
merizes with CB1R in neuronal cells in culture and in vivo (19).
In these systems, coactivation of both receptors results in a
negative cross-talk and a bidirectional cross-antagonism (19).
However, CB2R signaling can be conceivably more relevant in
non-differentiated cells, in which the receptor is highly abun-
dant, than in terminally differentiated cells such as neurons, in
which the receptor is scarce (3, 33). Specifically, CB2R, aswell as
GPR55, is notably overexpressed in a wide variety of cancer cell
lines and human malignant tumors (6, 11), in which they play
pivotal roles in controlling cancer cell fate (6, 11–14). It is
tempting to speculate that CB2R-GPR55 heteromers may also
exist and play pivotal signaling roles in other cells or tissues in
which they are overexpressed, such as hematopoietic cells (16)
or bones (34).
More and more studies have attempted to address the phys-
iological role of GPR55. This receptor has been implicated in
cancer, where it is generally linked with growth and prolifera-
tion (12–14). However, the molecular and cellular mechanisms
behind these effects are still unanswered. In addition, it has
been unclear whether GPR55’s effects on proliferation involve
CB2R or are independent. Considering the receptor heteromers
discussed above and knowing that CB2R and GPR55 have been
linked functionally in hematopoietic cells (16), we pursued the
hypothesis that CB2R-GPR55 heteromers might play a role in
the effects of GPR55 in cancer cells. Indeed, we found that these
complexes were able to form in HEK293 cells and in both
BT474 and T98G cancer cells and that they display a cross-talk
and cross-antagonism at the level of the cAMP and p-ERK-1/2
pathways. We also found different cell signaling effects at low
and high concentrations of THC and that this bimodal effect
required the presence of the heteromer. Our findings that THC
appears to be an antagonist of GPR55, at least at the level of cell
signaling both of the single receptor and within the CB2R-
GPR55 heteromer, were particularly surprising. Previous
reports have indeed suggested this (25), and the data we
obtained in three different cell lines as well as in amousemodel
of cancer in vivo support these conclusions. This is in line with
the general idea that, despite the potential relationship between
cannabinoid receptors and GPR55, their pharmacology is very
different (8, 35).
Finally, our discovery that CB2R-GPR55 complexes have
unique pharmacological and signaling properties and are criti-
cally involved in the response of cancer cells to THC both in
vitro and in vivo opens new doors to the development of com-
pounds targeting these heteromers as novel sites of interven-
tion for future cancer studies. Our results also shed light on the
possible molecular mechanisms underlying the well known but
still poorly understood biphasic effects of cannabinoids, which
have been reported for several decades regarding their action
on food intake, motor behavior, and anxiety, among others
(36–38).
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